Loading clinical trials...
Loading clinical trials...
A Phase IIa, Non-Randomized, Open-Label Dose Expansion Trial of Isunakinra in Combination With Pembrolizumab in Patients With Metastatic or Unresectable, Locally Advanced Colorectal Cancer
Conditions
Interventions
isunakinra
Locations
2
United States
USC/Norris Cancer Center
Los Angeles, California, United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
Start Date
January 30, 2025
Primary Completion Date
June 1, 2026
Completion Date
December 1, 2026
Last Updated
March 31, 2026
NCT05759728
NCT07328087
NCT07213570
NCT06889610
NCT05200442
NCT07050394
Lead Sponsor
Buzzard Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions